16,400 Shares in MBX Biosciences, Inc. (NYSE:MBX) Purchased by Barclays PLC

Barclays PLC bought a new position in MBX Biosciences, Inc. (NYSE:MBX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 16,400 shares of the company’s stock, valued at approximately $426,000.

Other institutional investors have also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. purchased a new position in MBX Biosciences during the 3rd quarter valued at about $155,499,000. NEA Management Company LLC bought a new stake in shares of MBX Biosciences during the 3rd quarter valued at about $93,904,000. Wellington Management Group LLP purchased a new position in shares of MBX Biosciences during the third quarter worth about $74,261,000. RA Capital Management L.P. purchased a new position in shares of MBX Biosciences during the third quarter worth about $39,264,000. Finally, Maven Securities LTD bought a new position in shares of MBX Biosciences in the third quarter worth approximately $1,299,000.

Analysts Set New Price Targets

Several equities research analysts have issued reports on MBX shares. JPMorgan Chase & Co. started coverage on shares of MBX Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $30.00 target price for the company. Guggenheim began coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They set a “buy” rating and a $44.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of MBX Biosciences in a research report on Tuesday, October 8th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $40.00 price target on the stock.

MBX Biosciences Trading Down 6.2 %

Shares of NYSE MBX opened at $9.89 on Friday. MBX Biosciences, Inc. has a one year low of $9.65 and a one year high of $27.50. The company’s 50 day simple moving average is $18.45.

MBX Biosciences (NYSE:MBX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.72) by ($0.06). As a group, sell-side analysts predict that MBX Biosciences, Inc. will post -13.21 EPS for the current fiscal year.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.